ESOC 2025 | The potential application of blood biomarkers to understand the mechanisms of hemorrhagic stroke
Maria Alonso De Leciñana, MD, PhD, La Paz University Hospital, Madrid, Spain, discusses the potential application of blood-based biomarkers to understand the mechanisms of hemorrhagic stroke and to develop new protective drugs. Dr Leciñana highlights her research on the protein content of extracellular vesicles to understand profiles of proteomic expression that are linked to a better prognosis. This interview took place at the 11th European Stroke Organisation Conference (ESOC) in Helsinki, Finland.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
Yes, I think a really promising application of blood biomarkers is research. Research in mechanisms of disease to find out any target to develop new protective drugs. For example, in my laboratory, we are working on the protein content of extracellular vesicles and we have found there is a certain profile of proteomic expression in these vesicles, circulating vesicles, that are linked to good prognosis...
Yes, I think a really promising application of blood biomarkers is research. Research in mechanisms of disease to find out any target to develop new protective drugs. For example, in my laboratory, we are working on the protein content of extracellular vesicles and we have found there is a certain profile of proteomic expression in these vesicles, circulating vesicles, that are linked to good prognosis. These are certain proteins that are related to functions such as inhibition of oxidation or apoptosis. So we are now trying to synthesize these proteins and to test them in preclinical trials to verify if they are really protective against cellular damage in hemorrhage to further develop this potential therapy into clinical trials, Phase I clinical trials. We are just at the beginning but this is really promising and I think this is a real application of blood biomarkers at the moment.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
